Collectively, these data provide evidence that EBV‐miR‐BART18‐3p promotes CRC development by activating de novo lipogenesis in CRC cells through the SIRT1/HIF‐1α/LDHA/FASN axis and suggest that EBV‐miR‐BART18‐3p may serve as a novel therapeutic target for CRC treatment. Here, FASN is linked to colorectal carcinoma.